Rigel Pharmaceuticals, Inc. Annual report pursuant to Section 13 and 15(d)

Annual report pursuant to Section 13 and 15(d)

LEASE AGREEMENTS (Tables)

LEASE AGREEMENTS (Tables)

12 Months Ended

Dec. 31, 2017

Schedule of changes in liability related to sublease agreement

The changes in the liability related to the sublease agreement during the years ended December 31, 2017, 2016 and 2015 were as follows (in thousands):


Balance at January 1, 2015	$	9,269
Accretion of deferred liability		559
Amortization of deferred liability		(3,363)
Balance at December 31, 2015		6,465
Accretion of deferred liability		357
Amortization of deferred liability		(3,362)
Balance at December 31, 2016		3,460
Increase in deferred liability		495
Accretion of deferred liability		157
Amortization of deferred liability		(3,828)
Balance at December 31, 2017	$	284

Schedule of future minimum lease payments and obligations under noncancelable operating lease, net of sublease receipts

At December 31, 2017, future minimum lease payments and obligations under our noncancelable operating lease, net of expected sublease receipts, were as follows (in thousands):


	Operating		Sublease
For years ending December 31,	Lease		Receipts		Net
2018	$	9,593	$	(3,942)	$	5,651
2019		9,321		(4,192)		5,129
2020		9,694		(4,360)		5,334
2021		10,082		(4,534)		5,548
2022 and thereafter		11,362		(5,110)		6,252
Total minimum payments required	$	50,052	$	(22,138)	$	27,914